leucogen: Clinical Trials

7 trials of leucogen, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 2 active not recruiting, 1 not yet recruiting. 7 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 37Completed 4, Active not recruiting 2, Not yet recruiting 1
Phase 21Completed 1

Follow leucogen: new trials by email Literature Review of leucogen trials Research Report on leucogen

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC
5-fu, Lobaplatin, Placebo - Nasopharyngeal Carcinoma, Leucogen
Phase 3Not yet recruitingSun Yat-sen University1322023-04-012023-03-22
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Asparaginase, Asparaginase Erwinia chrysanthemi, Cytarabine - Acute Myeloid Leukemia, Down Syndrome
Phase 3Active not recruitingChildren's Oncology Group2802015-12-232026-08-19
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase, Blinatumomab - Recurrent B Acute Lymphoblastic Leukemia
Phase 3Active not recruitingNational Cancer Institute (NCI)6692014-12-172026-10-21
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Asparaginase, Bortezomib, Cytarabine - Acute Myeloid Leukemia, Leukemia Cutis
Phase 3CompletedNational Cancer Institute (NCI)16452011-07-062026-06-02
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Asparaginase, Cyclophosphamide, Cytarabine - Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Phase 2 / Phase 3CompletedNational Cancer Institute (NCI)632008-07-142020-04-13
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Asparaginase, Biospecimen Collection, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia
Phase 3CompletedChildren's Oncology Group2182008-01-152024-07-15
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Asparaginase, Cyclophosphamide, Cytarabine - T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
Phase 3CompletedNational Cancer Institute (NCI)18952007-01-302026-06-23

Conditions studied

Leukemia, Myeloid, Acute (2)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Burkitt Lymphoma (1)  ·  Down Syndrome (1)  ·  Leukemia, Biphenotypic, Acute (1)  ·  Myelodysplastic Syndromes (1)  ·  Myeloproliferative Disorders (1)  ·  Nasopharyngeal Carcinoma (1)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Sarcoma, Myeloid (1)

Sponsors

National Cancer Institute (NCI) (4)  ·  Children's Oncology Group (2)  ·  Sun Yat-sen University (1)

Countries

Australia (6)  ·  Canada (6)  ·  New Zealand (6)  ·  United States (6)  ·  Puerto Rico (4)  ·  China (1)  ·  Saudi Arabia (1)  ·  Switzerland (1)

Top investigators

Jason N Berman (1)  ·  Joanne M Hilden (1)  ·  Patrick A Brown (1)  ·  Richard Aplenc (1)  ·  Stuart S Winter (1)  ·  William B Slayton (1)

Results publications

PMID 28419486, PMID 29812996, PMID 30138085, PMID 30773463, PMID 30987448, PMID 32029509, PMID 32414848, PMID 32552472, PMID 32813610, PMID 33242441, PMID 33651090, PMID 34302711, PMID 34596937, PMID 34855461, PMID 35349331, PMID 36603187, PMID 36815378, PMID 37257143, PMID 37267439, PMID 37556734, PMID 38295280, PMID 40294366, PMID 40533067, PMID 40568722, PMID 41124669, PMID 41592282, PMID 42085603, PMID 42085640

NIH funding

U10CA098543 (5), U10CA180886 (5)